ClinicalTrials.gg
WithdrawnNCT06984341Updated Aug 5, 2026

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of P-CD19CD20-ALLO1 Cells and Cyclophosphamide in Systemic Lupus Erythematosus, sponsored by Genentech, Inc.. Withdrawn at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Decision of Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche — 2 open to participants now, 4 under way, 1 of them phase 3. Lupus Erythematosus, Systemic · Hoffmann-La Roche.

Enrollment
14th of 14
0 · median 65
Started
2026
with 2 others
Phase 1
5 of 14
1 open now
Registered
12th of 14
by date

Among the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, this one is the 14th largest by enrollment, is one of 3 that started in 2026, is one of 5 in phase 1, and was the 12th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

2 of the 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Lupus Erythematosus, Systemic by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and tolerability of P-CD19CD20-ALLO1 in participants with highly active, severe, refractory SLE with or without lupus nephritis (LN). This study includes a dose-escalation stage followed by an expansion stage. It will also evaluate the cellular kinetics (CK), pharmacodynamics (PD), and efficacy of P-CD19CD20-ALLO1.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Lupus Nephritis
  • CAR-T therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

18-75 years old

SLE diagnosis per 2019 EULAR/ACR classification criteria ≥ 24 weeks

Autoantibody positive and low complement at screening

Treatment : Failed ≥ 2 treatments for at least 3 months

Highly active disease:

SLEDAI-2K ≥ 8 (excluding alopecia, headache, and fever; additional protocol-specified requirements to enhance specificity of findings)

BILAG-2004 cat A in ≥ 1 organ system and/or cat B in ≥ 2 organ systems (excluding constitutional, musculoskeletal, and/or mucocutaneous organ systems for category B)

PGA score ≥ 1.0 on a 0 to 3 VAS

For patients with lupus nephritis:

-proven Class III or IV (± Class V) active LN per 2018 ISN/RPS criteria within 12 months of screening

Modified NIH activity index ≥ 1/24

UPCR ≥ 1g/g

Key Exclusion criteria:

Participants who are pregnant, breastfeeding, or intend to become pregnant within the timeframe in which is required

Prior treatment with CAR T-cell therapy, B-cell-targeting T-cell-dependent bispecific antibody, gene therapy product, total body irradiation, allograft organ transplant, or hematopoietic stem cell transplant

Significant organ impairment (renal, hepatic, cardiac, or pulmonary) or uncontrolled medical disease which, in the investigator's opinion would preclude patient participation or that may require treatment with systemic or during the study

Active severe or unstable neuropsychiatric disease

Protocol-specified active or chronic infections, recent major episode of infection

High-risk medical conditions (e.g. high bleeding risk, history of cancer, recent major surgery, history of HLH/MAS, substance abuse within the previous year)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Dose Escalation

    Participants with SLE (with or without LN) will receive the following interventions and dose escalated per protocol: Biological: P-CD19CD20-ALLO1 Drug: Cyclophosphamide Drug: Fludarabine Drug: Rimiducid

    Biological: P-CD19CD20-ALLO1 Cells · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rimiducid

  • Experimental
    Dose Expansion (LN cohort)

    Participants with SLE (with LN) will receive the following interventions at or below the maximum tolerated dose (MTD), as determined in the dose escalation stage per protocol: Biological: P-CD19CD20-ALLO1 Drug: Cyclophosphamide Drug: Fludarabine Drug: Rimiducid

    Biological: P-CD19CD20-ALLO1 Cells · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rimiducid

  • Experimental
    Dose Expansion (ERL cohort)

    Participants with SLE (with ERL) will receive the following interventions at or below the maximum tolerated dose (MTD), as determined in the dose escalation stage per protocol: Biological: P-CD19CD20-ALLO1 Drug: Cyclophosphamide Drug: Fludarabine Drug: Rimiducid

    Biological: P-CD19CD20-ALLO1 Cells · Drug: Cyclophosphamide · Drug: Rimiducid

Interventions

  • BiologicalP-CD19CD20-ALLO1 Cells

    P-CD19CD20-ALLO1 cells will be administered intravenously as per the schedule specified in the protocol.

  • Cyclophosphamide will be administered intravenously.

  • Fludarabine will be administered intravenously.

  • Rimiducid will be used as a rescue therapy in the event of the occurrence of severe or life-threatening adverse events. It will be administered intravenously.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs) at Each Dose Level of P-CD19CD20-ALLO1

    Time frame: Day 1 up to Day 29

  2. Number of Participants With Adverse Events (AEs)

    Time frame: Up to 5 years

Secondary outcomes

  1. Number of Chimeric Antigen Receptor (CAR) Transgene Copies in Blood Assessed by Droplet Digital Polymerase Chain Reaction (ddPCR)

    Time frame: Up to 5 years

  2. B-cell Levels in the Blood

    Time frame: Up to 5 years

  3. Percentage of Participants who Achieve Sustained Drug-free Definition of Remission in SLE (DORIS)

    Drug-free DORIS is defined as a SLEDAI-2K = 0 and a PGA \<0.5 (on a 3-point PGA-visual analog scale \[VAS\]), without corticosteroids or other immunosuppressants.

    Time frame: From Week 24 through Week 52

  4. Number of Participants With Anti-CAR T Antibodies

    Time frame: Up to 5 years

07

Study locations

2 sites
  • University of Alabama at Birmingham: The Kirklin Clinic
    Birmingham, Alabama 35233, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Nov 2033, 88 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 22, 2025
StartEst.
Jun 30, 2026
Primary completionEst.
Nov 1, 2033
CompletionEst.
Nov 1, 2033
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06984341
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 22, 2025
Start date
Jun 30, 2026 (estimated)
Primary completion
Nov 1, 2033 (estimated)
Completion
Nov 1, 2033 (estimated)
Last update
Aug 5, 2026

Study contacts

Clinical Trials
study director · Genentech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion